Daunorubicin and adriamycin in the treatment of leukemia.
D000328:Adult; D000741:Anemia, Aplastic / Q000139:chemically induced; D001145:Arrhythmias, Cardiac / Q000139:chemically induced; D001792:Blood Platelets / Q000187:drug effects; D002986:Clinical Trials as Topic; D003630:Daunorubicin / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D004317:Doxorubicin / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D005069:Evaluation Studies as Topic; D005260:Female; D006474:Hemorrhagic Disorders / Q000139:chemically induced; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D007958:Leukocyte Count / Q000187:drug effects; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D012075:Remission, Spontaneous; D013921:Thrombocytopenia / Q000139:chemically induced
D004317:Doxorubicin; D003630:Daunorubicin